Bayer gets EU go-ahead for Xofigo
This article was originally published in Scrip
Executive Summary
Bayer HealthCare has won approval from the European Commission for its prostate cancer drug Xofigo (radium Ra 223 dichloride) with plans for a first launch in Germany.